Ann: RHY Signs first ColoSTAT site for Clinical Trial - Study 7, page-6

My prediction is if study 6 returns good results we’ll see a significant bounce above 20c. That’ll give us a good idea of what Colostat is capable of. Let’s not forget we’re sitting on a MC of $15M yet colorectal ca diagnostics is $100M++ in Australia alone (never mind the EU and India and wherever else Rhythm have patents). Benchmarks nailed on time and on budget. Strong financials. Significant derisking. Great team. Commercial partnerships in the works. All this with a SP currently 25% under IPO. Undervalued in my opinion.